NASDAQ:DRRX

DURECT - DRRX Stock Forecast, Price & News

$0.54

-0.01 (-2.18%)

(As of 10/6/2022 03:42 PM ET)

Add

Compare

Today's Range: $0.53
▼
$0.58
50-Day Range: $0.44
▼
$0.91
52-Week Range: $0.36
▼
$1.32

Volume: 5,564 shs
Average Volume: 242,774 shs
Market Capitalization: $123.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

DURECT MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
1.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.19
Upright™ Environmental Score
News Sentiment: 0.13
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$79,015 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.15) to ($0.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

969th out of 1,075 stocks

Pharmaceutical Preparations Industry

483rd out of 537 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for DURECT.

2.0

Short Interest

Percentage of Shares Shorted
1.47% of the float of DURECT has been sold short.
Short Interest Ratio / Days to Cover
DURECT has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in DURECT has recently increased by 14.63%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
DURECT does not currently pay a dividend.
Dividend Growth
DURECT does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
DURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for DURECT is -1.19.

2.3

News and Social Media Coverage

News Sentiment
DURECT has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for DURECT this week, compared to 1 article on an average week.
Search Interest
8 people have searched for DRRX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DURECT insiders have bought more of their company's stock than they have sold. Specifically, they have bought $79,015.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of DURECT is held by insiders.
Percentage Held by Institutions
43.14% of the stock of DURECT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for DURECT are expected to decrease in the coming year, from ($0.15) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DURECT is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DURECT is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DURECT has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About DURECT (NASDAQ:DRRX) Stock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Stock News Headlines

October 6, 2022 | finance.yahoo.com

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

September 28, 2022 | nasdaq.com

Innocoll To Make $2 Mln Payment To DURECT On First Commercial Sale Of POSIMIR

October 6, 2022 | Investing Trends (Ad)

How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors

According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).

September 26, 2022 | nasdaq.com

Health Care Sector Update for 09/26/2022: SGEN,LVTX,AMEH,SIGA,DRRX - Nasdaq

September 26, 2022 | finance.yahoo.com

Innocoll and DURECT Announce U.S. launch of POSIMIR®

September 13, 2022 | streetinsider.com

Form 8-K ProMIS Neurosciences For: Sep 12 - StreetInsider.com

September 6, 2022 | benzinga.com

Durect (DRRX) – DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - Benzinga

August 23, 2022 | msn.com

Durect's Return On Capital Employed Insights - msnNOW

October 6, 2022 | Investing Trends (Ad)

"The Most Critical Metal for Global Economies"

The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.

August 23, 2022 | benzinga.com

Durect's Return On Capital Employed Insights - Benzinga

August 12, 2022 | benzinga.com

$1.7 Million Bet On Offerpad Solutions? Check Out These 3 Penny Stocks Insiders Are Buying - Benzinga

August 9, 2022 | americanbankingnews.com

DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com

August 8, 2022 | finance.yahoo.com

Rainbows and Unicorns: DURECT Corporation (NASDAQ:DRRX) Analysts Just Became A Lot More Optimistic - Yahoo Finance

August 8, 2022 | finance.yahoo.com

Rainbows and Unicorns: DURECT Corporation (NASDAQ:DRRX) Analysts Just Became A Lot More Optimistic

August 5, 2022 | benzinga.com

Why Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving Premarket - Benzinga

August 5, 2022 | benzinga.com

Why Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday’s Mid-Day Session - Benzinga

August 5, 2022 | finance.yahoo.com

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs - Yahoo Finance

August 5, 2022 | seekingalpha.com

Durect GAAP EPS of -$0.05, revenue of $2.08M (NASDAQ:DRRX) - Seeking Alpha

August 5, 2022 | finance.yahoo.com

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2022 | in.investing.com

DURECT Corp Reports In-Line Q2 EPS By Investing.com - Investing.com India

August 4, 2022 | finance.yahoo.com

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs

August 3, 2022 | nasdaq.com

United Therapeutics (UTHR) Q2 Earnings Lag Estimates - Nasdaq

July 27, 2022 | finance.yahoo.com

DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4

July 24, 2022 | investorplace.com

6 Penny Stocks With 1000% Upside Potential - InvestorPlace

July 15, 2022 | finance.yahoo.com

Shareholders in DURECT (NASDAQ:DRRX) are in the red if they invested five years ago - Yahoo Finance

July 15, 2022 | finance.yahoo.com

Shareholders in DURECT (NASDAQ:DRRX) are in the red if they invested five years ago

July 13, 2022 | fortune.com

Get ready for ‘a pretty ugly earnings season’ - Fortune

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Company Calendar

Last Earnings: 11/01/2021
Today: 10/06/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DRRX
CUSIP: N/A
CIK: 1082038
Web: www.durect.com
Phone: (408) 777-1417
Fax: 408-777-3577
Employees: 79
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,260,000.00
Net Margins: -292.71%
Pretax Margin: -292.71%
Return on Equity: -76.42%
Return on Assets: -46.26%

Debt

Debt-to-Equity Ratio: 0.54
Current Ratio: 5.71
Quick Ratio: 5.51

Sales & Book Value

Annual Sales: $13.98 million
Price / Sales: 8.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.25 per share
Price / Book: 2.17

Miscellaneous

Outstanding Shares: 227,760,000
Free Float: 216,831,000
Market Cap: $123.81 million
Optionable: Optionable
Beta: 1.27

Key Executives

Dr. James E. Brown D.V.M. (Age 65)
Co-Founder, CEO, Pres & Director
Comp: $859.68k

Ms. Judy R. Joice (Age 65)
Sr. VP of Operations & Corp. Quality Assurance
Comp: $436.99k

Dr. Norman L. Sussman M.D. (Age 69)
Chief Medical Officer
Comp: $570.32k

Mr. Timothy M. Papp
Chief Financial Officer

Ms. Jian Li M.B.A. (Age 52)
Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec.

Dr. Andrew R. Miksztal Ph.D.
VP of Pharmaceutical R&D and Principal Scientist

Mr. Steve Helmer J.D.
VP & Chief Patent Counsel

Dr. WeiQi Lin
Exec. VP of R&D and Principal Scientist

Dr. Su Il Yum Ph.D. (Age 83)
Exec. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DRRX Stock - Frequently Asked Questions

Should I buy or sell DURECT stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DRRX shares.
View DRRX analyst ratings or view top-rated stocks.
How have DRRX shares performed in 2022?: DURECT's stock was trading at $0.9859 at the start of the year. Since then, DRRX stock has decreased by 43.6% and is now trading at $0.5557.
View the best growth stocks for 2022 here.
When is DURECT's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our DRRX earnings forecast.
How were DURECT's earnings last quarter?: DURECT Co. (NASDAQ:DRRX) posted its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analyst estimates of $2.18 million. DURECT had a negative net margin of 292.71% and a negative trailing twelve-month return on equity of 76.42%. During the same period in the prior year, the business earned ($0.05) EPS.

What other stocks do shareholders of DURECT own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).
What is DURECT's stock symbol?: DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How do I buy shares of DURECT?: Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is DURECT's stock price today?: One share of DRRX stock can currently be purchased for approximately $0.56.
How much money does DURECT make?: DURECT (NASDAQ:DRRX) has a market capitalization of $126.57 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36,260,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.
How can I contact DURECT?: DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

DURECT - DRRX Stock Forecast, Price & News

DURECT MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows